02:12 PM EST, 11/18/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) down 4% in afternoon trade, said Tuesday that it was selected to present three clinical and one preclinical posters at the San Antonio Breast Cancer Symposium taking place in Texas next month.

Three poster presentations include updated biomarker data from BriaCell's Phase 3 study and updated survival data from the Phase 2 study of the company's lead candidate, Bria-IMT, plus immune check point inhibitor in metastatic breast cancer, a statement said.

"With three poster presentations, including two potentially high impact late-breaking clinical posters, we will be presenting significant amounts of data to the most prominent breast cancer scientific experts and cancer specialists as we advance our therapies with the goal of developing better clinical outcomes for cancer patients," said chief executive William Williams.

BriaCell shares are down $0.46 to $10.94 on the Toronto Stock Exchange.

Price: 10.86, Change: -0.54, Percent Change: -4.74